Introduction
============

Defects in the maxillofacial skeleton generally are reconstructed with autogenous bone grafts \[[@b1-mprs-36-037]\]. Although autogenous bone performs best, its supply is limited. Bone harvesting at donor sites, moreover, incurs surgical stress and complications such as pain, bleeding and postoperative infection. To obviate the need for graft harvesting with its accompanying morbidity, bone substitutes and bone production via bioengineering are much sought-after alternatives. Ideally, bone grafts should be non-immunogenic and non-inflammatory, and should allow for rapid osteoinductivity, rapid osteoconductivity and rigid osteointegration \[[@b2-mprs-36-037],[@b3-mprs-36-037]\].

Necessary for bone tissue formation at defect sites are osteogenic cells that induce it, a scaffold that can accommodate the proliferation and differentiation of cells at appropriate locations, and the osteoinductive growth factors that stimulate its differentiation induction. The osteoinductive growth factors include bone morphogenetic proteins (BMPs), transforming growth factors (TGF-*β*), insulin-like growth factor and others, among which BMPs are known to be the most effective \[[@b4-mprs-36-037]--[@b6-mprs-36-037]\]. BMPs, first noted by Urist \[[@b7-mprs-36-037]\] in 1965, have been investigated for their bone-growth-inducing properties. Specifically, BMPs can induce differentiation of mesenchymal cells and stem cells into osteoblasts and chondroblasts, as well as induce ectopic bone formation in soft tissue \[[@b8-mprs-36-037]--[@b10-mprs-36-037]\]. BMPs are also important in embryogenesis at bone fracture sites. BMPs induce new bone chiefly via the endochondral pathway. BMPs released from a carrier initially induce formation of cartilage tissue around that carrier, which tissue gradually is replaced by bone \[[@b11-mprs-36-037]\]. Happily, it is expected that therapeutic application of recombinant human BMP-2 (rhBMP-2) in bone generation and augmentation will become possible \[[@b12-mprs-36-037]--[@b14-mprs-36-037]\].

Tricalcium phosphate (Ca~3~(PO~4~)~2~; TCP), a synthetic, biodegradable bone-promoting and replacement biomaterial, has been extensively investigated for the repair of various shapes and sizes of bone defect caused by trauma, tumor resection or skeletal abnormalities, owing to its good bio-compatibility and osteointegrative properties \[[@b15-mprs-36-037]\]. TCP is generally regarded as highly osteoconductive but not osteoinductive \[[@b16-mprs-36-037]--[@b20-mprs-36-037]\]. In the present study, we used TCP as a non-immunogenic, inorganic carrier for rhBMP-2, which has osteoinductive properties sufficient for realization of composite biomaterial. We studied osteoinduction in rabbit calvarial bone defects, comparing an experimental group treated with rhBMP-2-coated TCP with a control group (treated with TCP only). We compared the bone formation capability of TCP with and without rhBMP-2 and assessed TCP as an rhBMP-2 carrier.

Materials and Methods
=====================

1.. Animals and group design
----------------------------

Eight New Zealand adult female rabbits older than 6 months, weighing between 2.5 and 3.5 kg, were used in the study. The animals were housed individually in standard rabbit cages at an ambient temperature of 20°C under a 12/12 hour light/dark cycle. The animals had free access to drinking water and standard laboratory pellets.

All of the rabbits underwent an ovariectomy under general anesthesia (intramuscular Ketamine HCl \[50 mg/kg; Ketalar^®^; Yuhan, Seoul, Korea\] and Xylazine \[10 mg/kg; Rumpun^®^; Bayer Korea, Seoul, Korea\]; mixture ratio: 5/1) and sterile conditions. After a healing period of 4 weeks, an operation was performed on the cranium. In preparation, the dorsal area of the cranium was shaved and the surgical field was prepared with iodine solution. A midline incision was performed on the skull, and the periosteum was reflected laterally, exposing the parietal bones. Two symmetrical, 8-mm-wide bone defects were formed using a round bur under constant irrigation. Special care was taken to avoid injury to the dura ([Fig. 1](#f1-mprs-36-037){ref-type="fig"}).

The left defects (the experimental group) were grafted with rhBMP-2-coated TCP, and the right defects (the control group) with TCP only. After adequate hemostasis, the periosteum was closed with a 4-0 vicryl suture and the skin with a 4-0 nylon suture. The animals were given 5 mg/kg gentamycin postoperatively to prevent infection. The postoperative courses were uneventful.

The rabbits were sacrificed at the 1st, 2nd, 4th, and 8th weeks postoperatively, two each time. The skulls were harvested and subjected to radiographic and histological examination. All of the experiments were conducted in accordance with the ethical committee of the Medical Research Institute of Dong-A University.

2.. Preparation of recombinant human bone morphogenetic protein-2-coated tricalcium phosphate
---------------------------------------------------------------------------------------------

TCP coated with rhBMP-2 (Cowellmedi Co., Busan, Korea) was employed as the bone grafting material. The rhBMP-2 was genetically engineered in *Escherichia coli* and activated using high-BMP-2-expressing U2OS cells (human osteosarcoma cell line). The mature forms of rhBMP-2 were cloned from U2OS cells. The high density culture was performed and refined protein. Finally, dimerized rhBMP-2 was purified by affinity chromatography using a Heparin column. The rhBMP-2, in 0.1 mg/mL concentrations, was adsorbed onto the TCP by incubating the TCP for 24 hours.

3.. Micro-computed tomography analysis
--------------------------------------

At each time point (1st week, 2nd week, 4th week, 8th week), the calvaria of two rabbits were scanned by micro-computed tomography (*μ*CT; FLEX^TM^ for flatform X-O^TM^; GMI, Northridge, CA, USA) horizontally, coronally and sagittally for measurement of the bone mineral density (BMD) at the 1st, 2nd, 4th, and 8th weeks ([Fig. 2](#f2-mprs-36-037){ref-type="fig"}). The BMD (mg/mL) was taken within the cylindrical region of interest (ROI), that is, the defect site, which showed a higher radiopacity on the *μ*CT view.

4.. Histology
-------------

Each specimen was fixed in a 10% formaldehyde solution, decalcified in formic acid for 48 hours, and embedded in paraffin. Serial cross-sections (5 *μ*m) were cut through the large diameter of the defect and stained with hematoxylin-eosin (H&E) and Masson's trichrome, with which the cellular reaction and bone formation were evaluated. The slides were photographed using an image analysis system (Axiovision 4.3, Carl Zeiss, Jena, Germany).

5.. Immunohistochemistry
------------------------

Additional sections were mounted on glass slides for immunohistochemical analysis of the expressions of osteoprotegerin (OPG), the receptor activator of nuclear factor *κ*B ligand (RANKL), and the receptor activator of nuclear factor *κ*B (RANK) in the rabbit calvarial defects. These regulate osteoclast formation, differentiation, and activity. The slides were coated with 4 *μ*m on the dried slice, and maintained at 60°C in an oven for an hour. After removal of the paraffin by washing four times with xylene for five minutes, the slides were washed with distilled water after hydration with alcohol. The slides were then washed three times for 3 minutes with buffer solution. To remove the intrinsic peroxide, the sample was reacted with 0.3% H~2~O~2~ solution. Subsequently it was washed 4 times with buffer solution to inhibit reactions within the tissue after reacting with blocking serum (Goat Immunocruz staining system; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) for an hour and reacting overnight with a dilution (OPG 1:120, RANKL 1:40, RANK 1:90) of each primary antibody, OPG (sc-8468; Santa Cruz Biotechnology Inc.), RANK (sc-7625; Santa Cruz Biotechnology Inc.), RANKL (sc-7692; Santa Cruz Biotechnology Inc.). The sample was washed again with buffer solution, reacted with a secondary Ab labeled Biotin for an hour, washed four times more with buffer solution, and reacted with the enzyme conjugate streptavidin (Goat Immunocruz staining system; Santa Cruz Biotechnology Inc.) for an hour.

The immunohistochemical analysis was performed individually by two examiners blind to the treatment conditions. The relative staining intensity was assessed for each antibody. The samples were scored as follows: − = no immunoreactivity; + = weak but visible staining; ++ = moderate staining; +++ = strong staining intensity.

Results
=======

1.. Clinical observation
------------------------

All of the animals recovered from the operation and healed without complications. Both the TCP and the rhBMP-2-coated TCP were well adapted into critical bone defects. In the experimental group, the graft material was rigid and well osseointegrated ([Fig. 3](#f3-mprs-36-037){ref-type="fig"}) at the 1st and 2nd weeks compared with the control group.

2.. Micro-computed tomography analysis
--------------------------------------

The results of the BMD (mg/mL) measurement within the ROI for each group are listed in [Table 1](#t1-mprs-36-037){ref-type="table"}. In both groups, the BMD value increased significantly from the 1st to the 8th week. The defects grafted with rhBMP-2-coated TCP; however, had higher BMD values than those grafted with TCP only. The mean total BMD in the experimental group (246.196 mg/mL) was higher than in the control group (221.642 mg/mL). The standard deviation of BMD values was 47.481 in the control group and 30.438 in the experimental group. The mean BMD difference (28.242 mg/mL) between the two groups through the 1st, 2nd and 4th weeks was higher than that (13.49 mg/mL) at the 8th week ([Table 1](#t1-mprs-36-037){ref-type="table"}).

3.. Histological findings
-------------------------

### 1). H&E staining

By the 1st week post-grafting, the control group had not formed bone, while the experimental group showed aspects of partial bone formation. By the 2nd weeks, bone formation within the control group was observed, along with advanced bone formation and mineralization in the experimental group. By the 4th weeks, both groups showed more advanced calcification, and by the 8th week, both presented complete calcification ([Fig. 4](#f4-mprs-36-037){ref-type="fig"}).

### 2). Masson's trichrome staining

Both groups in the 1st week showed a dark blue color indicating collagen and bone formation within the TCP, though the experimental group, in the 1st and 2nd weeks, more strongly. Both groups by the 4th weeks showed continuous activation of bone remodeling. Further, both groups manifested more specific aspects in the 8th weeks, specifically collagen and reddish-colored matured bone ([Fig. 5](#f5-mprs-36-037){ref-type="fig"}).

4.. Immunohistochemical findings
--------------------------------

### 1). Osteoprotegerin

More specific OPG expression was observed in the experimental group than in the control group up to 2 weeks after grafting. Expression increased in both groups from the 1st to the 2nd weeks. The expression period was one week earlier in the experimental group. Expression was similar in both groups in the 4th week ([Table 2](#t2-mprs-36-037){ref-type="table"}, [Fig. 6](#f6-mprs-36-037){ref-type="fig"}).

### 2). Receptor activator of nuclear factor *κ*B ligand

RANKL expression, related to osteoclast activity, was observed within the grafting material in both the experimental and control groups. The 1st and 2nd weeks after grafting, a specific increment of RANKL expression was observed in the experimental group; after the 4th and 8th weeks, a similar expression developed in the control group ([Table 3](#t3-mprs-36-037){ref-type="table"}, [Fig. 7](#f7-mprs-36-037){ref-type="fig"}).

### 3). Receptor activator of nuclear factor *κ*B

The results for RANK expression were similar to those for OPG and RANKL. At the 1st and 2nd weeks after grafting, the experimental group showed more specific RANKL expression than the control group. The levels decreased by the 4th and 8th weeks, showing similar expression aspects between the two groups ([Table 4](#t4-mprs-36-037){ref-type="table"}, [Fig. 8](#f8-mprs-36-037){ref-type="fig"}). The experimental group's expression of OPG, RANKL, and RANK were higher in the 1st and 2nd weeks but decreased to the level of the control group in the 4th and 8th weeks.

Discussion
==========

A successful bone replacement material must be bio-compatible, biodegradable and osteoconductive so as to attract cells to the defect site and promote the formation of new bone. The most direct approach to successful development of artificial bone is to produce a material having a composition similar to that of natural bone. TCP, composed of calcium and phosphate ions, the same ions that make up the bulk of natural bone mineral, is widely utilized to increase the osteoconductive characteristics of bone replacement therapies. However, TCP does not have osteoinductive properties. In the present study, TCP was coated with rhBMP-2, giving it osteoconductive properties.

BMPs are members of the TGF-*β* super-family, a highly conserved group of cytokines with widespread expression in tissues and a variety of functions in embryology, the development stage. There is convincing evidence that BMPs are powerful inducers of osteoblast differentiation and bone formation. Over 20 different isoforms of BMPs have been identified; BMP-2, -4 and -7 are thought to be most important in the skeletal system \[[@b21-mprs-36-037],[@b22-mprs-36-037]\]. Higuchi *et al*. \[[@b23-mprs-36-037]\], using rat mandible through-and-through bone defects, observed a larger quantity of new bone in the experimental group (rhBMP-2 0.1 *μ*g/*μ*L with a polylactic acid-polyglycolic acid copolmer/gelatin sponge carrier) than in the control group (the same carrier without rhBMP-2). Matin *et al*. \[[@b24-mprs-36-037]\] observed that rhBMP-2 prevented residual ridge resorption after tooth extraction. They found larger numbers of proliferating cells and densely populated differentiating mesenchyme cells, as well as a greater total bone area and increased bone height on the rhBMP-2. This finding replicates others, that of rapid bone formation and mineralization in the experimental group due to the osteogenic capability of rhBMP-2.

Various inorganic carriers are used as BMP delivery systems \[[@b25-mprs-36-037]--[@b28-mprs-36-037]\]. The ideal scaffold material requires specific mechanical properties, biocompatibility, biodegradability, absence of allergic reaction, disease transmission, delivery of the osteoinductive factor, gross architecture, shaping, clinical handling and regulatory issues. No currently available scaffold material meets all of these demands. Misch and Dietsh \[[@b29-mprs-36-037]\] argued that TCP, despite its porosity, is appropriate for mixed use in enhancing the maneuverability of osteogenetic substances such as BMPs, or for use in osteoconductive grafting materials, due to its high stability and abrasion resistance.

We selected TCP as the rhBMP-2 carrier because it is the most stable and appropriate material from the bone formation standpoint. We genetically engineered rhBMP-2 in E. coli and adsorbed it onto the TCP in a 100 *μ*g/mL concentration. Pang *et al*. \[[@b30-mprs-36-037]\] reported of rhBMP-4 combined with adsorbent collagen sponge or ß-TCP, within the selected rhBMP-4 dose range (0.025 mg/mL, 0.05 mg/mL), there appeared to be no meaningful differences in bone formation. Other workers, applying rhBMP-2 concentration of 10, 50, 100, 200 mg/L, found that proliferation and differentiation of mesenchymal stem cell depends on concentration. Particularly, osteoblast differentiation accelerated at 100 mg/L, 200 mg/L \[[@b31-mprs-36-037]\]. We selected 0.1 mg/mL concentration of rhBMP-2 for the experiment. However, studies on the proper rhBMP-2 concentration with carrier TCP are lacking, as are those on rhBMP-2-release periods.

Both calcium deficiency and ovariectomy can induce osteoporosis experimentally. However, while calcium deficiency does not seem to impair bone healing, the effect of ovariectomy is not known \[[@b32-mprs-36-037]\]. Ovariectomy decreases bone density in rabbits \[[@b33-mprs-36-037]\]. Therefore, we performed ovariectomies on rabbits to reduce BMD and induce osteoporosis, and used TCP, consisting of calcium and phosphate ions, to supply calcium to low-calcium bone.

Recent research identifies OPG, RANKL and RANK as factors affecting bone formation and remodeling. In the case of OPG increment, pre-osteoclasts are inhibited from activating or differentiating. Also, osteoclast necrosis increases and bone resorption decreases. Bone formation, then, predominates. RANKL increment produces an opposite effect, activating and differentiating pre-osteoclasts, so that bone resorption increases. RANKL induces many inter-cellular reactions by bonding to RANK in pre-osteoclasts and osteoclasts \[[@b34-mprs-36-037]--[@b36-mprs-36-037]\]. Bone resorption and osteogenesis increments are required for active bone remodeling. Therefore, high expression levels of OPG, RANKL and RANK indicate active bone remodeling. rhBMP-2 promotes expression of cyclooxygenase-2 and the osteoclast differentiation factor in osteoblast-like cells, regulating osteoclastogenesis \[[@b37-mprs-36-037]\]. The mitogenic, chemotactic and differentiating effect of BMPs may help to mediate coupling of bone formation to resorption. We can determine changes of bone regeneration rates by closely monitoring the changes of OPG, RANKL and RANK.

In this study, we grafted rhBMP-2-coated TCP and un-coated TCP onto left- and right-side defects to the skull of ovariectomized rabbits and evaluated the extents of bone formation and remodeling in radiological, *μ*CT, histological and immunohistochemical analyses (OPG, RANKL, RANK).

In the *μ*CT analysis results, the BMP group showed faster bone formation and remodeling than the control group in the 1st and 2nd weeks. Results were the same for the histological and immunohistochemical evaluations. Collagen formation, early calcification, and mineralization occurred earlier in the rhBMP-2-coated TCP. OPG, RANKL, and RANK expressed at higher rates in the experimental group in the 1st and 2nd weeks. We can assume from these findings that vigorous bone remodeling occurs as osteoclast differentiation is accelerated by rhBMP-2 at the early stages. By the 4th and 8th weeks, there were no significant histological or immunohistochemical differences, because the graft material had sufficiently matured in both groups. In summation, TCP is crucial as the rhBMP-2 carrier, enabling the latter to effect bone formation, remodeling, and mineralization at the early stages.

Conclusion
==========

In this study, we grafted either rhBMP-2-coated TCP or TCP only onto calvaria defects in ovariectomized rabbits and evaluated the extents of bone formation and remodeling.

1.  In the radiological results, bone remodeled faster in the experimental group than the control group. The BMD estimation by *μ*CT indicated especially high values for the experimental group at the 1st, 2nd, and 4th weeks. However, there was no significant difference by the 8th week.

2.  In the histological results (H&E, Masson's Trichrome stain), bone formed rapidly in the experimental group, with remodeling and calcification in the 1st and 2nd weeks. However, there was no significant difference between the experimental and control groups in the 4th and 8th weeks.

3.  In the immunohistochemical results, the OPG, RANKL, and RANK all expressed at higher rates in the experimental group at the 1st and 2nd weeks than the control group. This implies that osteoblasts and osteoclasts are more active at the early stages.

Overall, rhBMP-2-coated TCP led to rapid bone formation, remodeling, and calcification, owing to rhBMP-2's osteogenic effect. TCP performed properly as a carrier for rhBMP-2. The use of rhBMP-2 coated TCP had a synergic effect on bone healing, and especially, bone remodeling and maturation. All of these findings suggest strongly that rhBMP-2-coated TCP is a promising clinical application advance in maxillofacial surgery for critical size defects.

![(A) The surgical field was prepared with an iodine solution. (B) Dissection and elevation of periosteum. (C) 8 mm bony defect formation on the parietal bone lateral to the mid-sagittal suture. (D) Defect on left side was grafted with tricalcium phosphate (TCP) coated with recombinant human bone morphogenetic protein-2, and opposite side (right) was grafted with TCP only.](mprs-36-037f1){#f1-mprs-36-037}

![Micro-computed tomography analysis. (A) Horizontal view. (B) Coronal view. (C) Sagittal view.](mprs-36-037f2){#f2-mprs-36-037}

![Gross appearance. Defect on left side was grafted with tricalcium phosphate (TCP) coated with recombinant human bone morphogenetic protein-2, and opposite side (right) was grafted with TCP only. (A) One week after surgery. (B) Two weeks after surgery. (C) Four weeks after surgery. (D) Eight weeks after surgery.](mprs-36-037f3){#f3-mprs-36-037}

![Histologic photograph (H&E, ×100). (A) Microphotograph at 1 week after graft in control site. (B) Microphotograph at 1 week after graft in experimental site. (C) Micro-photograph at 2 weeks after graft in control site. (D) Microphotograph at 2 weeks after graft in experimental site. (E) Microphotograph at 4 weeks after graft in control site. (F) Microphotograph at 4 weeks after graft in experimental site. (G) Microphotograph at 8 weeks after graft in control site. (H) Microphotograph at 8 weeks after graft in experimental site. GM, graft material; HB, host bone.](mprs-36-037f4){#f4-mprs-36-037}

![Histologic photograph (Masson's trichrome stain, ×100). (A) Microphotograph at 1 week after graft in control site. (B) Microphotograph at 1 week after graft in experimental site. (C) Microphotograph at 2 weeks after graft in control site. (D) Microphotograph at 2 weeks after graft in experimental site. (E) Microphotograph at 4 weeks after graft in control site. (F) Microphotograph at 4 weeks after graft in experimental site. (G) Microphotograph at 8 weeks after graft in control site. (H) Microphotograph at 8 weeks after graft in experimental site. GM, graft material; HB, host bone.](mprs-36-037f5){#f5-mprs-36-037}

![Osteoprotegerin (OPG) antibody reaction (×100). (A) Regenerating bone at 1 week after graft in control site. (B) Regenerating bone at 1 week after graft in experimental site. (C) Regenerating bone at 2 weeks after graft in control site. (D) Regenerating bone at 2 weeks after graft in experimental site. (E) Regenerating bone at 4 weeks after graft in control site. (F) Regenerating bone at 4 weeks after graft in experimental site. (G) Regenerating bone at 8 weeks after graft in control site. (H) Regenerating bone at 8 weeks after graft in experimental site. Black arrows indicate OPG antibody reaction. OPG positive signals appear as a red color.](mprs-36-037f6){#f6-mprs-36-037}

![Receptor activator of nuclear factor *κ*B ligand (RANKL) antibody reaction (×100). (A) Regenerating bone at 1 week after graft in control site. (B) Regenerating bone at 1 week after graft in experimental site. (C) Regenerating bone at 2 weeks after graft in control site. (D) Regenerating bone at 2 weeks after graft in experimental site. (E) Regenerating bone at 4 weeks after graft in control site. (F) Regenerating bone at 4 weeks after graft in experimental site. (G) Regenerating bone at 8 weeks after graft in control site. (H) Regenerating bone at 8 weeks after graft in experimental site. Black arrows indicate RANKL antibody reaction. RANKL positive signals appear as a red color.](mprs-36-037f7){#f7-mprs-36-037}

![Receptor activator of nuclear factor *κ*B (RANK) antibody reaction (×100). (A) Regenerating bone at 1 week after graft in control site. (B) Regenerating bone at 1 week after graft in experimental site. (C) Regenerating bone at 2 weeks after graft in control site. (D) Regenerating bone at 2 weeks after graft in experimental site. (E) Regenerating bone at 4 weeks after graft in control site. (F) Regenerating bone at 4 weeks after graft in experimental site. (G) Regenerating bone at 8 weeks after graft in control site. (H) Regenerating bone at 8 weeks after graft in experimental site. Black arrows indicate RANK antibody reaction. RANK positive signals appear as a red color.](mprs-36-037f8){#f8-mprs-36-037}

###### 

Bone mineral density (mg/mL) in critical bone defects

  Post-graft period   Case I    Case II             
  ------------------- --------- --------- --------- ---------
  1st week            205.398   222.454   203.539   227.261
  2nd week            157.481   210.760   221.389   240.168
  4th week            167.580   208.584   267.579   283.187
  8th week            287.879   284.630   262.294   292.521

###### 

Osteoprotegerin expression after tricalcium phosphate graft

  Post-graft period   Control group                                                                              Experimental group
  ------------------- ------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------
  1st week            [++](#tfn3-mprs-36-037){ref-type="table-fn"}                                               [++](#tfn3-mprs-36-037){ref-type="table-fn"}/[+++](#tfn4-mprs-36-037){ref-type="table-fn"}
  2nd week            [+](#tfn2-mprs-36-037){ref-type="table-fn"}/[++](#tfn3-mprs-36-037){ref-type="table-fn"}   [++](#tfn3-mprs-36-037){ref-type="table-fn"}
  4th week            [++](#tfn3-mprs-36-037){ref-type="table-fn"}                                               [++](#tfn3-mprs-36-037){ref-type="table-fn"}
  8th week            [−](#tfn1-mprs-36-037){ref-type="table-fn"}                                                [+](#tfn2-mprs-36-037){ref-type="table-fn"}

−, no immunoreactivity;

+, weak but visible staining;

++, moderate staining;

+++, strong staining intensity.

###### 

Receptor activator of nuclear factor *κ*B ligand expression after tricalcium phosphate graft

  Post-graft period   Control group                                                                              Experimental group
  ------------------- ------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------
  1st week            [++](#tfn7-mprs-36-037){ref-type="table-fn"}                                               [+++](#tfn8-mprs-36-037){ref-type="table-fn"}
  2nd week            [++](#tfn7-mprs-36-037){ref-type="table-fn"}                                               [++](#tfn7-mprs-36-037){ref-type="table-fn"}/[+++](#tfn8-mprs-36-037){ref-type="table-fn"}
  4th week            [+](#tfn6-mprs-36-037){ref-type="table-fn"}/[++](#tfn7-mprs-36-037){ref-type="table-fn"}   [+](#tfn6-mprs-36-037){ref-type="table-fn"}/[++](#tfn7-mprs-36-037){ref-type="table-fn"}
  8th week            [−](#tfn5-mprs-36-037){ref-type="table-fn"}/[+](#tfn6-mprs-36-037){ref-type="table-fn"}    [−](#tfn5-mprs-36-037){ref-type="table-fn"}/[+](#tfn6-mprs-36-037){ref-type="table-fn"}

−, no immunoreactivity;

+, weak but visible staining;

++, moderate staining;

+++, strong staining intensity.

###### 

Receptor activator of nuclear factor *κ*B expression after tricalcium phosphate graft

  Post-graft period   Control group                                                                                Experimental group
  ------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------
  1st week            [++](#tfn11-mprs-36-037){ref-type="table-fn"}                                                [+++](#tfn12-mprs-36-037){ref-type="table-fn"}
  2nd week            [+](#tfn10-mprs-36-037){ref-type="table-fn"}/[++](#tfn11-mprs-36-037){ref-type="table-fn"}   [+++](#tfn12-mprs-36-037){ref-type="table-fn"}
  4th week            [+](#tfn10-mprs-36-037){ref-type="table-fn"}                                                 [+](#tfn10-mprs-36-037){ref-type="table-fn"}
  8th week            [−](#tfn9-mprs-36-037){ref-type="table-fn"}/[+](#tfn10-mprs-36-037){ref-type="table-fn"}     [−](#tfn9-mprs-36-037){ref-type="table-fn"}/[+](#tfn10-mprs-36-037){ref-type="table-fn"}

−, no immunoreactivity;

+, weak but visible staining;

++, moderate staining;

+++, strong staining intensity.
